{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:54:21Z","timestamp":1773154461066,"version":"3.50.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,9,1]]},"DOI":"10.1097\/qai.0b013e3181dd911e","type":"journal-article","created":{"date-parts":[[2010,4,27]],"date-time":"2010-04-27T06:41:01Z","timestamp":1272350461000},"page":"49-57","source":"Crossref","is-referenced-by-count":169,"title":["Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir\/Lamivudine Versus Tenofovir\/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1\u2013Infected Adults: 48-Week Results From the ASSERT Study"],"prefix":"10.1097","volume":"55","author":[{"given":"Frank A","family":"Post","sequence":"first","affiliation":[]},{"given":"Graeme J","family":"Moyle","sequence":"additional","affiliation":[]},{"given":"Hans J\u00fcrgen","family":"Stellbrink","sequence":"additional","affiliation":[]},{"given":"Pere","family":"Domingo","sequence":"additional","affiliation":[]},{"given":"Daniel","family":"Podzamczer","sequence":"additional","affiliation":[]},{"given":"Martin","family":"Fisher","sequence":"additional","affiliation":[]},{"given":"Anthony G","family":"Norden","sequence":"additional","affiliation":[]},{"given":"Matthias","family":"Cavassini","sequence":"additional","affiliation":[]},{"given":"Armin","family":"Rieger","sequence":"additional","affiliation":[]},{"given":"Marie-Aude","family":"Khuong-Josses","sequence":"additional","affiliation":[]},{"given":"Teresa","family":"Branco","sequence":"additional","affiliation":[]},{"given":"Helen C","family":"Pearce","sequence":"additional","affiliation":[]},{"given":"Naomi","family":"Givens","sequence":"additional","affiliation":[]},{"given":"Cindy","family":"Vavro","sequence":"additional","affiliation":[]},{"given":"Michael L","family":"Lim","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R3-6-20210131","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"R4-6-20210131","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, Emtricitabine and Efavirenz Vs Zidovudine, Lamivudine and Efavirenz for HIV.","volume":"354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"R5-6-20210131","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.1016\/j.jinf.2004.08.031","article-title":"Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment-case report and review of literature.","volume":"51","author":"Malik","year":"2005","journal-title":"J Infect"},{"key":"R6-6-20210131","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1086\/499048","article-title":"Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions.","volume":"42","author":"Zimmermann","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R7-6-20210131","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1468-1293.2008.00691.x","article-title":"Spectrum of chronic kidney disease in HIV-infected patients.","volume":"10","author":"Campbell","year":"2009","journal-title":"HIV Med"},{"key":"R8-6-20210131","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/QCO.0b013e328320ffec","article-title":"Recent developments in HIV and the kidney.","volume":"22","author":"Post","year":"2009","journal-title":"Curr Opin Infect Dis"},{"key":"R9-6-20210131","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1086\/524061","article-title":"Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.","volume":"197","author":"Goicoechea","year":"2008","journal-title":"J Infect Dis"},{"key":"R11-6-20210131","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0149-2918(01)80132-6","article-title":"Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.","volume":"23","author":"Hetherington","year":"2001","journal-title":"Clin Ther"},{"key":"R13-6-20210131","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir.","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"R14-6-20210131","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","article-title":"Use of nuceloside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.","volume":"371","author":"Sabin","year":"2008","journal-title":"Lancet"},{"key":"R15-6-20210131","doi-asserted-by":"crossref","first-page":"F17","DOI":"10.1097\/QAD.0b013e32830fe35e","article-title":"SMART\/INSIGHT and D:A:D Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.","volume":"22","year":"2008","journal-title":"AIDS"},{"key":"R16-6-20210131","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0b013e32833562c5","article-title":"Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.","volume":"24","author":"Martinez","year":"2010","journal-title":"AIDS"},{"key":"R19-6-20210131","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/QAD.0b013e3283359253","article-title":"Kidney function and the risk of cardiovascular events in HIV-1-infected patients.","volume":"24","author":"George","year":"2010","journal-title":"AIDS"},{"key":"R20-6-20210131","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/QAD.0b013e3283262a64","article-title":"Kidney tubular abnormalities in the presence of imparied glomerular function in HIV patients treated with tenofovir.","volume":"23","author":"Labarga","year":"2009","journal-title":"AIDS"},{"key":"R21-6-20210131","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/QAD.0b013e32832cbcc2","article-title":"Randomized, double-blind, placebo-matched, multicenter trial of abacavir\/lamivudine and tenofovir\/emtricitabine with lopinavir\/ritonavir for initial HIV treatment.","volume":"23","author":"Smith","year":"2009","journal-title":"AIDS"},{"key":"R22-6-20210131","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/01.aids.0000247574.33998.03","article-title":"A randomised comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.","volume":"20","author":"Moyle","year":"2006","journal-title":"AIDS"},{"key":"R23-6-20210131","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/QAI.0b013e3181aa12d5","article-title":"A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir\/lamivudine or tenofovir\/emtricitabine in HIV-1-infected patients with virolocial suppression.","volume":"51","author":"Martinez","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R24-6-20210131","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1053\/j.ajkd.2009.07.012","article-title":"Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis.","volume":"54","author":"Hall","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R25-6-20210131","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1046\/j.1523-1755.2000.00847.x","article-title":"Tubular proteinuria defined by a study of Dents (CLCN5 mutation) and other tubular diseases.","volume":"57","author":"Norden","year":"2000","journal-title":"Kidney Int"},{"key":"R26-6-20210131","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1097\/QAD.0b013e3283112b8e","article-title":"The 3-year renal safety of a tenofovir disoproxil fumarate vs a thymidine analogue-containing regimen in antiretroviral-naive patients.","volume":"22","author":"Gallant","year":"2008","journal-title":"AIDS"},{"key":"R27-6-20210131","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/QAD.0b013e3282f4706d","article-title":"Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease.","volume":"22","author":"Kalayjian","year":"2008","journal-title":"AIDS"},{"key":"R28-6-20210131","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1086\/533468","article-title":"Severe renal dysfunction and risk factors associated with renal impairment in HIV-1 infected adults in Africa initiating antiretroviral therapy.","volume":"46","author":"Reid","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R29-6-20210131","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1086\/648445","article-title":"Long-term evolution and determinants of renal function in HIV-infected patients who began receiving combination antiretroviral therapy in 1997-1999, ANRS CO8 APROCO-COPILOTE.","volume":"49","author":"Leport","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R31-6-20210131","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1097\/QAD.0b013e3283313c91","article-title":"HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy.","volume":"23","author":"Choi","year":"2009","journal-title":"AIDS"},{"key":"R32-6-20210131","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"CD4+ count-guided interruption of antiretroviral treatment.","volume":"355","author":"El-Sadr","year":"2006","journal-title":"N Eng J Med"},{"key":"R33-6-20210131","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/QAD.0b013e32831cc129","article-title":"Interruption of antiretroviral therapy is associated with increased plasma cystatin C.","volume":"23","author":"Mocroft","year":"2009","journal-title":"AIDS"},{"key":"R35-6-20210131","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1086\/598507","article-title":"Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.","volume":"48","author":"Rodriguez-Novoa","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R36-6-20210131","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1468-1293.2009.00716.x","article-title":"Tenofovir-associated renal and bone toxicity.","volume":"10","author":"Woodward","year":"2009","journal-title":"HIV Med"},{"key":"R37-6-20210131","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1093\/ndt\/gfm898","article-title":"Lysosomal enzymuria is a feature of hereditary Fanconi syndrome and is related to elevated CI-mannose-6-P-receptor excretion.","volume":"23","author":"Norden","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R38-6-20210131","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa0906768","article-title":"Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.","volume":"361","author":"Sax","year":"2009","journal-title":"N Engl J Med"},{"key":"R39-6-20210131","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1056\/NEJMe038173","article-title":"HIV therapy-what do we know, and when do we know it?","volume":"349","author":"Skolnik","year":"2003","journal-title":"N Engl J Med"},{"key":"R40-6-20210131","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1310\/hct1002-65","article-title":"Virologic response and safety of the abacavir\/lamivudine fixed-dose formulation as part of highly active antiretroviral therapy: analyses of six clinical studies.","volume":"10","author":"Ha","year":"2009","journal-title":"HIV Clin Trials"},{"key":"R42-6-20210131","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1365-2265.2008.03490.x","article-title":"Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence.","volume":"70","author":"Preiss D and Sattar","year":"2009","journal-title":"Clin Endocrinol"},{"key":"R43-6-20210131","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jama.2009.943","article-title":"Novel and conventional biomarkers for prediction of incident cardiovascular events in the community.","volume":"302","author":"Melander","year":"2009","journal-title":"JAMA"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00126334-201009010-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T07:26:56Z","timestamp":1618039616000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-201009010-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3181dd911e","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9,1]]}}}